Success Metrics

Clinical Success Rate
95.2%

Based on 20 completed trials

Completion Rate
95%(20/21)
Active Trials
7(23%)
Results Posted
85%(17 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_4
2
7%
Ph phase_1
3
10%
Ph phase_2
9
30%
Ph phase_3
14
47%

Phase Distribution

3

Early Stage

9

Mid Stage

16

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
3(10.7%)
Phase 2Efficacy & side effects
9(32.1%)
Phase 3Large-scale testing
14(50.0%)
Phase 4Post-market surveillance
2(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.0%

20 of 23 finished

Non-Completion Rate

13.0%

3 ended early

Currently Active

7

trials recruiting

Total Trials

30

all time

Status Distribution
Active(7)
Completed(20)
Terminated(3)

Detailed Status

Completed20
Recruiting7
Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
30
Active
7
Success Rate
95.2%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (10.7%)
Phase 29 (32.1%)
Phase 314 (50.0%)
Phase 42 (7.1%)

Trials by Status

completed2067%
recruiting723%
withdrawn27%
terminated13%

Recent Activity

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT06959225Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Recruiting
NCT06958211Phase 3

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Recruiting
NCT07049575Phase 1

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Recruiting
NCT05750823Phase 2

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Completed
NCT07368673Phase 4

Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial

Completed
NCT05696392Phase 4

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Terminated
NCT06548360Phase 3

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

Recruiting
NCT05764161Phase 3

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Completed
NCT06804811Phase 3

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Recruiting
NCT06259669

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Recruiting
NCT06627335

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Recruiting
NCT05755438Phase 3

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Completed
NCT06238817Phase 3

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Completed
NCT04057573Phase 3

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Completed
NCT04052425Phase 3

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Completed
NCT04896385Phase 2

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

Completed
NCT05906628Phase 2

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Completed
NCT05456529Phase 3

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Completed
NCT05635838Phase 2

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Completed
NCT05593432Phase 2

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Completed

Drug Details

Intervention Type
DRUG
Total Trials
30